All In Biotech

Drug Trial Radar · NCT06008197

A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients

Randomized Trial to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Heart Failure Patients With Left Ventricular Ejection Fraction Greater Than or Equal to 40% Hospitalized Due to an Episode of Acute Decompensated Heart Failure (REDEFINE-HF)

Last checked: Nov 19, 2026Latest source record: Sep 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 5,200 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

5,200

Planned (sponsor's estimate)

Start

Jan 17, 2024

Primary completion

Nov 2027

Study completion Dec 2027

Sponsor

Lead sponsor
Colorado Prevention CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
St. Luke's Hospital, Kansas City, Missouri; Bayer
First posted
Aug 23, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Finerenone will be compared to placebo to determine efficacy and safety of treatment in patients hospitalized with acute decompensated heart failure (HF) and mildly reduced or preserved left ventricular ejection fraction.

Conditions

  • Heart Failure
  • Acute Heart Failure

Interventions

  • FinerenoneDrug

    Oral finerenone

  • PlaceboDrug

    Matching oral placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Composite of total HF events and cardiovascular (CV) death.Time frame: Ongoing, up to ~30 months
  2. Number of serious adverse events.Time frame: Ongoing, up to ~30 months
  3. Number of adverse events leading to discontinuation of study drug.Time frame: Ongoing, up to ~30 months

Locations

356 sites in 26 countries. Site status is shown where the registry gives one.

  • Birmingham, AL Investigative Site 10012

    Birmingham, Alabama · Recruiting

  • Fairhope, AL Investigative Site 10004

    Fairhope, Alabama · Recruiting

  • Huntsville, AL Investigative Site 10026

    Huntsville, Alabama · Recruiting

  • Glendale, AZ Investigative Site 10096

    Glendale, Arizona · Recruiting

  • Phoenix, AZ Investigative Site 10115

    Phoenix, Arizona · Recruiting

  • Scottsdale, AZ Investigative Site 10003

    Scottsdale, Arizona · Recruiting

  • Chula Vista, CA Investigative Site 10111

    Chula Vista, California · Recruiting

  • Huntington Beach, CA Investigative Site 10031

    Huntington Beach, California · Recruiting

  • Los Angeles, CA Investigative Site 10089

    Los Angeles, California · Recruiting

  • Sacramento, CA Investigative Site 10024

    Sacramento, California · Recruiting

  • San Francisco, CA Investigative Site 10023

    San Francisco, California · Recruiting

  • Tarzana, CA Investigative Site 10409

    Tarzana, California · Recruiting

  • Van Nuys, CA Investigative Site 10109

    Van Nuys, California · Recruiting

  • West Hills, CA Investigative Site 10013

    West Hills, California · Recruiting

  • Aurora, CO Investigative Site 10001

    Aurora, Colorado · Recruiting

  • Denver, CO Investigative Site 10005

    Denver, Colorado · Recruiting

  • Bradenton, FL Investigative Site 10125

    Bradenton, Florida · Recruiting

  • Brooksville, FL Investigative Site 10077

    Brooksville, Florida · Recruiting

  • Fort Lauderdale, FL Investigative Site 10114

    Fort Lauderdale, Florida · Recruiting

  • Fort Myers, FL Investigative Site 10076

    Fort Myers, Florida · Recruiting

  • Hialeah, FL Investigative Site 10104

    Hialeah, Florida · Recruiting

  • Jacksonville, FL Investigative Site 10028

    Jacksonville, Florida · Recruiting

  • Miami, FL Investigative Site 10105

    Miami, Florida · Recruiting

  • Miami, FL Investigative Site 10040

    Miami, Florida · Recruiting

  • Miramar, FL Investigative Site 10113

    Miramar, Florida · Not yet recruiting

  • Tamarac, Florida Investigative Site 10127

    Tamarac, Florida · Recruiting

  • Atlanta, GA Investigative Site 10022

    Atlanta, Georgia · Recruiting

  • Duluth, GA Investigative Site 10083

    Duluth, Georgia · Recruiting

  • Boise, Idaho Investigative Site 10073

    Boise, Idaho · Recruiting

  • Chicago, IL Investigative Site 10062

    Chicago, Illinois · Recruiting

  • Glenview, IL Investigative Site 10021

    Glenview, Illinois · Recruiting

  • Naperville, IL Investigative Site 10025

    Naperville, Illinois · Recruiting

  • Peoria, IL Investigative Site 10019

    Peoria, Illinois · Recruiting

  • Peoria, IL Investigative Site 10010

    Peoria, Illinois · Recruiting

  • Indianapolis, IN Investigative Site 10074

    Indianapolis, Indiana · Recruiting

  • Indianapolis, IN Investigative Site 10008

    Indianapolis, Indiana · Recruiting

  • Merrillville, IN Investigative Site 10064

    Merrillville, Indiana · Recruiting

  • Kansas City, KS Investigative Site 10060

    Kansas City, Kansas · Recruiting

  • Cynthiana, KY Investigative Site 10124

    Cynthiana, Kentucky · Recruiting

  • Lexington, KY Investigative Site 10080

    Lexington, Kentucky · Recruiting

Showing 40 of 356 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.